Abstract
BackgroundImmune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have